EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
The Human Side of Pharma BD: Patience, Persistence, and Truly Understanding Client Needs
Client Relations Officer, PozeScaf Inc
Pragathi Yadhati is a Client Relations Officer at PozeScaf Inc and Chief Business Officer for healthtech startups ScribeJoy and NuMd Since she has advised pharma organisations on relationshipfocused business development and strategic partnerships fundraising and connecting companies with investors She served on the advisory board of IIT Jodhpur and brought a peoplecentered empathetic approach to...
Articles
Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches
Centre for Drug Evaluation and Research CDER a fundamental component of Food and Drug Administration implements guidelines on various drug products vaccines and biologicals Pharmaceutical industries seeking approval to market various therapeutic products must be in accordance with these guidelines
Research Insights
RNAi Therapeutic Platforms for Lung Diseases
Yu Fujita Fumitaka Takeshita Kazuyoshi Kuwano and Takahiro Ochiya Division of Molecular and Cellular Medicine National Cancer Center Research Institute Tokyo Japan Division of Respiratory Diseases Department of Internal Medicine Jikei University School of Medicine Tokyo Japan
Case Studies
Variation In Adverse Drug Reactions Listed In Product Information For Antidepressants And Anticonvulsants, Between The Usa And Europe: A Comparison Review Of Paired Regulatory Documents
Abstract Objective To compare consistency of adverse drug reaction ADR data in publicly available product information documents for brand drugs between the USA and Europe and to assess the usefulness of information for prescribers and patients Design A comparison review of product info
Techno Trends
I-Mab Introduced Novel Felzartamab Antibody for Primary Membranous Nephropathy
IMab has introduced groundbreaking antibody known as felzartamab This investigational monoclonal antibody specifically targets CD and is being developed as a potential therapy
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Beyond the Cold Chain
Dr. Mary Manoranjani Addanki, PhD, is an Associate Professor and Head of Pharmaceutics at Malla Reddy College of Pharmacy. With 17 years of expertise, she specialises in nanotechnology, pulmonary vaccines, and advanced drug delivery. An award-winning researcher and patent holder, her work focuses on stabilising vaccines and developing innovative dosage forms.
The Rapidly Evolving Landscape of Cancer Therapeutics
Rajesh Kumar is an Assistant Professor of Pharmaceutical Sciences at Kerala University of Health Sciences, India. He has been teaching Diploma, Bachelor, and Doctor of Pharmacy students for several years and is actively involved in research. He has authored more than 19 papers and is a reviewer for Bentham Science Publishers. His research includes applying the principles of pharmaceutical sciences, omics technologies, computational biology, and bioinformatics in the broad areas of cancer research, ethnopharmacology, drug delivery, targeting, and formulations.
Seetha Harilal is an Assistant Professor of Pharmacology at Kerala University of Health Sciences, India. She has several years of experience in teaching Diploma, Bachelor, and Doctor of Pharmacy students and is actively pursuing research. She has authored more than 22 papers and is a manuscript reviewer for Bentham Science Publishers, Frontiers in Public Health, Frontiers in Medicine, and Archives of Medical Research (Elsevier). Her research includes the diverse areas of pharmacology and therapeutics, phytopharmaceuticals, cancer research, neurological disorders, and the application of omics technologies, computational pharmacology, and bioinformatics.
Nanoemulsion - A Promising Nanocarrier for Dermal Drug Delivery in Psoriasis
Sindhoor S M is currently working as an Assistant Professor in the Department of Pharmaceutics at Sri Adichunchanagiri College of Pharmacy, Mandya, Karnataka. His areas of specialisation include nanotechnology-based drug delivery system, lipid-based formulations, Topical delivery and gastroretentive in situ gel systems. He has published eight papers based on nanotechnology and lipid-based drug delivery system in peer reviewed indexed journals. Presently he is involved in the development of lipid-based delivery systems.
Marina Koland, is Professor and Head of the Department of Pharmaceutics at the NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangalore. Her area of specialisation in research is mucoadhesive and nanoparticulate drug delivery. She has published 50 research papers in peer reviewed journals, presented papers at 10 National and 3 International Conferences and worked on several Nitte University funded projects. She is currently working on solid lipid nanoparticles and micelles as drug carriers for targeting.
Nano-Carrier based Smart Drug Delivery Systems
Sidharth Mehta, Researcher in Market Research domain at Prescient Healthcare Group, India. He is a Master’s in Pharmacy (Pharmaceutics) by qualification did his postgraduation from GJUS&T, Hisar, India. His research interests are mainly in the field of nanotechnology. In 2021, he spent a period at University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh (India) with an UGC-NRC project on “Development and Evaluation of Solid Lipid Nanoparticles as Drug Carrier for Topical Delivery of Leflunomide”. He has published several papers in international peer reviewed journals. He had done in-plant training in two pharmaceutical companies and improved his research skill as per industry standards. He worked hard on both his academic and practical skills, as a result of that he qualified national level pharmacy graduate test (GPAT) thrice and NIPER with good rank.
Nikita Yadav, she believes that you can achieve anything at any age. She is a Master’s in Pharmacy (Pharmaceutics) by qualification did her postgraduation from GJUS&T, Hisar, India. Her research interests are mainly in the field of nano- and micro-technology with the use of essentials and natural ingredients. She had many recent experiences like a course in Elsevier[Certified peer reviewer Course], in Good Clinical Practice by NIDA Clinical trials networkandin Regulatory affairs by Udemy.Also, she joined an NGO i.e., Aashman Foundation, which mainly work unconditionally on women empowerment, single income families and underprivileged children through relevant healthcare, innovative education, and environmental based livelihood programs. She also qualified national level pharmacy graduate test (GPAT) in 2020.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement